HCW Biologics (HCWB) Competitors

HCW Biologics (NASDAQ:HCWB) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Does the media refer more to HCWB or PDSB?

In the previous week, HCW Biologics and HCW Biologics both had 2 articles in the media. PDS Biotechnology's average media sentiment score of 0.63 beat HCW Biologics' score of 0.44 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PDS Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor HCWB or PDSB?

PDS Biotechnology received 65 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 69.61% of users gave PDS Biotechnology an outperform vote.

Company	Underperform	Outperform
HCW Biologics	Outperform Votes 6 100.00%	Underperform Votes No Votes
PDS Biotechnology	Outperform Votes 71 69.61%	Underperform Votes 31 30.39%

Do analysts rate HCWB or PDSB?

PDS Biotechnology has a consensus price target of $11.67, suggesting a potential upside of 677.78%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than HCW Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PDS Biotechnology	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Do insiders & institutionals believe in HCWB or PDSB?

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 49.9% of HCW Biologics shares are owned by insiders. Comparatively, 9.5% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more risk and volatility, HCWB or PDSB?

HCW Biologics has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.

Is HCWB or PDSB more profitable?

PDS Biotechnology has a net margin of 0.00% compared to HCW Biologics' net margin of -1,067.82%. PDS Biotechnology's return on equity of -139.57% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-1,067.82%	-2,516.84%	-132.95%
PDS Biotechnology	N/A	-139.57%	-67.22%

Which has preferable valuation and earnings, HCWB or PDSB?

HCW Biologics has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$2.84M	4.70	-$24.99M	-$1.00	-0.35
PDS Biotechnology	N/A	N/A	-$42.94M	-$1.16	-1.29

Summary

PDS Biotechnology beats HCW Biologics on 11 of the 17 factors compared between the two stocks.